<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pituitary</journal-id>
      <journal-title-group>
        <journal-title>Pituitary</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1386-341X</issn>
      <issn pub-type="epub">1573-7403</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21221818</article-id>
      <article-id pub-id-type="pmc">3146981</article-id>
      <article-id pub-id-type="publisher-id">289</article-id>
      <article-id pub-id-type="doi">10.1007/s11102-010-0289-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Neggers</surname>
            <given-names>Sebastian J. C. M. M.</given-names>
          </name>
          <address>
            <phone>+31-107032861</phone>
            <fax>+31-107033639</fax>
            <email>s.neggers@erasmusmc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Herder</surname>
            <given-names>Wouter W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Feelders</surname>
            <given-names>Richard A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van der Lely</surname>
            <given-names>A. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Department of Medicine, Erasmus University Medical Center Rotterdam, PO box 2040, 3000 CA Rotterdam, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>8</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2011</year>
      </pub-date>
      <volume>14</volume>
      <issue>3</issue>
      <fpage>253</fpage>
      <lpage>258</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>The efficacy of combined treatment in active acromegaly with both long-acting somatostatin analogs (SRIF) and pegvisomant (PEG-V) has been well established. The aim was to describe the PEG-V dose reductions after the conversion from daily PEG-V to combination treatment. To clarify the individual beneficial and adverse effects, in two acromegaly patients, who only normalized their insulin like growth factor (IGF-I) levels with high-dose pegvisomant therapy. We present two cases of a 31 and 44&#xA0;years old male with gigantism and acromegaly that were controlled subsequently by surgery, radiotherapy, SRIF analogs and daily PEG-V treatment. They were converted to combined treatment of monthly SSA and (twice) weekly PEG-V. High dose SSA treatment was added while the PEG-V dose was decreased during carful monitoring of the IGF-I. After switching from PEG-V monotherapy to SRIF analogs plus pegvisomant combination therapy IGF-I remained normal. However, the necessary PEG-V dose, to normalize IGF-I differed significantly between these two patients. One patient needed twice weekly 100&#xA0;mg, the second needed 60&#xA0;mg once weekly on top of their monthly lanreotide Autosolution injections of 120&#xA0;mg. The weekly dose reduction was 80 and 150&#xA0;mg. After the introducing of lanreotide, fasting glucose and glycosylated haemoglobin concentrations increased. Diabetic medication had to be introduced or increased. No changes in liver tests or in pituitary adenoma size were observed. In these two patients, PEG-V in combination with long-acting SRIF analogs was as effective as PEG-V monotherapy in normalizing IGF-I levels, although significant dose-reductions in PEG-V could be achieved. However, there seems to be a wide variation in the reduction of PEG-V dose, which can be obtained after conversion to combined treatment.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Pituitary tumor</kwd>
        <kwd>Acromegaly</kwd>
        <kwd>Acromegaly treatment</kwd>
        <kwd>Pegvisomant</kwd>
        <kwd>Combined treatment</kwd>
        <kwd>Somatostatin analogs</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media, LLC 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Pegvisomant, a growth hormone (GH) receptor antagonist is a highly effective medical therapy for acromegaly. Studies have reported on high efficacy of pegvisomant (PEG-V), alone or in combination with somatostatin analogs (SRIF) of&#xA0;&gt;90% to control insulin like growth factor (IGF-I) [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR4">4</xref>]. The necessary PEG-V dose to control IGF-I seems to be lower during combination therapy than with PEG-V alone [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The combination treatment is probably therefore more effective at equal weekly dose than PEG-V alone [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. There is a necessity to control IGF-I and GH has been well established since this will predict mortality [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. So combined treatment seems to be an attractive option.</p>
      <p>We present two cases of acromegaly patients who were controlled during daily, mono-therapy of PEG-V and were converted to combination treatment.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Subjects and methods</title>
      <sec id="Sec3">
        <title>Case report</title>
        <sec id="Sec4">
          <title>Case A</title>
          <p>A 31-years-old man was diagnosed with diabetes and gigantism since 1995, with a random GH of 220&#xA0;mU/l and an IGF-I 4.5 times the upper limit of normal (&#xD7; ULN). A macro adenoma of 3 cm with suprasellar extension, impingement of the chiasm and invasion in the left cavernous sinus which was assessed by the Magnetic Resonance Imaging (MRI). In 1996, the initial treatment was transsphenoidal surgery. Pathologist reported a pituitary adenoma which a positive immunohistochemical staining for GH. Postoperative the GH levels and IGF-I levels remained uncontrolled (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In 1997, 4 times daily subcutaneous injection of Octreotide 300&#xA0;&#x3BC;g was started and later converted to Octreotide LAR 30&#xA0;mg monthly. In 1997, additional radiotherapy of 45&#xA0;Gy in 25 fractions was given. In 1998, despite all these efforts IGF-I and GH remained elevated while other anterior pituitary hormones became deficient, which needed replacement therapy. Therefore, this patient was switched to pegvisomant therapy. Octreotide LAR was stopped in 1998 and daily PEG-V was increased up to 40&#xA0;mg daily until IGF-I was within the age adjusted normal limits [<xref ref-type="bibr" rid="CR4">4</xref>]. In October 2006 Lanreotide autosolution (LAN) was added and PEG-V was decreased in dose and frequency according to protocol. On pituitary MRI prior to the introduction of the LAN a remnant (8&#xA0;mm) of the adenoma was present in and around left cavernous sinus.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Biochemical parameters and medication of both patients before and during combination therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient A date</th><th align="left">1998</th><th align="left">2000</th><th align="left">2002</th><th align="left">2003&#xA0;</th><th align="left">Jan-07</th><th align="left">Apr-07</th><th align="left">Jul-07</th><th align="left">Oct-07</th></tr></thead><tbody><tr><td align="left">Acromegaly medication</td><td align="left">Octreotide<break/>LAR 30</td><td align="left">PEG-V 40<break/>OD</td><td align="left">PEG-V 40<break/>OD</td><td align="left">PEG-V 40<break/>OD</td><td align="left">LAN 120<break/>PEG-V 70<break/>mg TW</td><td align="left">LAN 120<break/>PEG-V 80<break/>mg TW</td><td align="left">LAN 120<break/>PEG-V 100<break/>mg TW</td><td align="left">LAN 120<break/>PEG-V 100<break/>mg TW</td></tr><tr><td align="left">GH &#x3BC;g/l</td><td align="left">42</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">IGF-I ULN (nmol/l)</td><td align="left">1.9 (73,9)</td><td align="left">0.98 (39.3)</td><td align="left">0.93 (37.3)</td><td align="left">0.93 (37.0)</td><td align="left">1.3 (55.7)</td><td align="left">1.0 (40.9)</td><td align="left">0.8 (31.4)</td><td align="left">0.5 (20.8)</td></tr><tr><td align="left">HbA1c</td><td align="left">6.9</td><td align="left">6.4</td><td align="left">6.1</td><td align="left">6.2</td><td align="left">8.4</td><td align="left">8.7</td><td align="left">9.0</td><td align="left">7.7</td></tr><tr><td align="left">Fasting glucose</td><td align="left">7.3</td><td align="left">4.9</td><td align="left">5.9</td><td align="left">6.5</td><td align="left">8.0</td><td align="left">9.4</td><td align="left">5.7</td><td align="left">3.8</td></tr><tr><td align="left">DM medication</td><td align="left">INN TD 5</td><td align="left">INN TD 5</td><td align="left">INN TD 5</td><td align="left">INN TD 5</td><td align="left">INN TD 5</td><td align="left">INN TrD 5</td><td align="left">INN TrD 5</td><td align="left">INN TD 5 Glargin 48&#xA0;IE OD</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient B date</th><th align="left">2003</th><th align="left">2004</th><th align="left">2005</th><th align="left">2006&#xA0;</th><th align="left">Jun-07</th><th align="left">Sep-07</th><th align="left">Dec-07</th><th align="left">Mar-07</th></tr></thead><tbody><tr><td align="left">Acromegaly medication</td><td align="left">Octreotide<break/>LAR 40</td><td align="left">PEG-V 30<break/>OD</td><td align="left">PEG-V 30<break/>OD</td><td align="left">PEG-V 30<break/>OD</td><td align="left">LAN 120<break/>PEG-V 50<break/>mg TW</td><td align="left">LAN 120<break/>PEG-V 80<break/>mg OW</td><td align="left">LAN 120<break/>PEG-V 60<break/>mg OW</td><td align="left">LAN 120<break/>PEG-V 60<break/>mg OW</td></tr><tr><td align="left">GH &#x3BC;g/l</td><td align="left">2.3</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">IGF-I ULN (nmol/l)</td><td align="left">1.93 (67.5)</td><td align="left">0.82 (28.6)</td><td align="left">0.96 (33.6)</td><td align="left">0.96 (32.9)</td><td align="left">0.3 (12.1)</td><td align="left">0.5 (16.6)</td><td align="left">0.9 (31.7)</td><td align="left">0.8 (29.8)</td></tr><tr><td align="left">HbA1c</td><td align="left">N/A</td><td align="left">6.6</td><td align="left">6.3</td><td align="left">6.4</td><td align="left">6.9</td><td align="left">7.8</td><td align="left">8.9</td><td align="left">7.4</td></tr><tr><td align="left">Fasting glucose</td><td align="left">5.7</td><td align="left">4.0</td><td align="left">4.6</td><td align="left">5.0</td><td align="left">6.9</td><td align="left">10.7</td><td align="left">8.9</td><td align="left">7.8</td></tr><tr><td align="left">DM medication</td><td align="left">none</td><td align="left">none</td><td align="left">none</td><td align="left">none</td><td align="left">none</td><td align="left">MT 500 TD</td><td align="left">MT 850 TrD</td><td align="left">MT 850 TrD</td></tr></tbody></table><table-wrap-foot><p><italic>LAN</italic> Lanreotide Autosolution (mg), <italic>PEG</italic>-<italic>V</italic> Pegvisomant (mg), <italic>OD</italic> Once Daily, <italic>OW</italic> Once Weekly, <italic>TW</italic> Twice Weekly, <italic>TD</italic> Twice Daily, <italic>TrD</italic> Trice Daily, <italic>INN</italic> glibenclamide (mg), <italic>MT</italic> metformin (mg) and N/A</p></table-wrap-foot></table-wrap></p>
        </sec>
        <sec id="Sec5">
          <title>Case B</title>
          <p>A 44-year-old man was diagnosed with acromegaly and osteoporosis since 1994. At the time of diagnose random GH serum levels were around 120&#xA0;mU/l while IGF-I serum levels were around 3.5 &#xD7; ULN. On MRI, he had a pituitary tumor of 2-cm with suprasellar extension, but without impingement of the chiasm and possible invasion of the right cavernous sinus. In 1994 he underwent transsphenoidal surgery. A tumor specimen revealed positive immunohistochemical staining for GH. After surgery, he was treated with radiotherapy (42 Gray in 32 fractions). After surgery and RT GH serum levels dropped to around 17&#xA0;&#x3BC;g/l. Three months post surgery IGF-I serum levels were decreased to 3.0&#xA0;&#xD7;&#xA0;ULN. In 1995, Octreotide was started (100&#xA0;&#x3BC;g t.i.d.) and converted to monthly Octreotide LAR 40&#xA0;mg in 1998. Although he developed panhypopituitarism and GH levels normalized, IGF-I levels remained elevated, around 1.9&#xA0;&#xD7;&#xA0;ULN (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In 2003, Octreotide LAR therapy was switched into PEG-V monotherapy. Daily PEG-V dosages of 30&#xA0;mg PEG-V were necessary to decrease IGF-I levels to within the age adjusted normal limits. In Marche 2007, LAN was added and PEG-V was decreased in dose and frequency. On pituitary MRI prior to the introduction of the LAN, a small (5&#xA0;mm) remnant of the adenoma was present close to the right cavernous sinus.</p>
        </sec>
      </sec>
      <sec id="Sec6" sec-type="materialsandmethods">
        <title>Methods</title>
        <p>After monthly LAN 120&#xA0;mg was started the intervals between visits were 8&#xA0;weeks to assess efficacy and safety. The initial dose of PEG-V was decreased with 50% and later a further stepwise decrease until IGF-I levels escaped (see results section). If IGF-I was above the upper limit of normal the dose was increased again until IGF-I levels were within the age adjusted normal range. If IGF-I fell below 0.5&#xA0;ULN PEG-V dose was decreased. After normalization of IGF-I during the combination treatment phase, subjects visited our outpatient clinic every 12&#x2013;16&#xA0;weeks. If a pegvisomant injection dose reached 100&#xA0;mg or more, the administration of pegvisomant was divided into 2 (equal) dosages that were injected twice weekly.</p>
        <p>From 2004 to 2009, IGF-I and GH concentrations were measured by an immunometric assays (Diagnostic Products Corporation, Los Angeles USA) and before by an immunoradiometric assays (Diagnostic Systems Laboratories, Texas USA). The IGF-I age adjusted reference ranges were used [<xref ref-type="bibr" rid="CR8">8</xref>]. But during PEG-V treatment the GH serum levels were not assessed.</p>
        <sec id="Sec7">
          <title>Safety assessment included</title>
          <p>Fasting glucose, glycosylated haemoglobin, EKG, serum concentrations of alkaline phosphatase (AF), &#x3B3;-glutamyltranspeptidase (&#x3B3;-GT), alanine aminotransferase (ALT), aspartate aminotransaminase (AST), lactate dehydrogenase (LD), total bilirubin and change in pituitary tumor volume. Tumor volume was assessed at baseline by MRI which was repeated every 12&#xA0;months. Change in pituitary adenoma size was assessed by the same neuro-radiologist.</p>
        </sec>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Results</title>
      <p>LAN 120&#xA0;mg was given every 4&#xA0;weeks. After the second administration of LAN 120&#xA0;mg PEG-V dose was decreased by 50% of the normal total weekly dose of the subjects. PEG-V was increase until IGF-I normalized after 3 and/or 6&#xA0;months (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Patient A was on 40&#xA0;mg PEG-V, daily. Patient&#x2019;s B original dose was 30&#xA0;mg a day of PEG-V. The dose reduction of PEG-V in patient A started with a dose decrease to twice weekly 70&#xA0;mg of PEG-V. Patient B decreased the PEG-V to twice weekly 50&#xA0;mg. After 3&#xA0;months patient A increased the dose to twice weekly 80&#xA0;mg and patient B decreased the dose to 80&#xA0;mg once weekly. After 6&#xA0;months the final dose for patient A was twice weekly 100&#xA0;mg and for patient B once weekly 60&#xA0;mg of PEG-V.</p>
      <p>The weekly PEG-V dose reduction for patient A was 80&#xA0;mg and patient B, 150&#xA0;mg weekly, both with a normalized IGF-I (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p><italic>1</italic> Octreotide LAR 30&#xA0;mg, <italic>2a</italic> Pegvisomant 40&#xA0;mg daily, <italic>2b</italic> Pegvisomant 30&#xA0;mg daily, <italic>3a</italic> and <italic>b</italic> Somatuline autosolution and Pegvisomant</p></caption><graphic xlink:href="11102_2010_289_Fig1_HTML" id="MO1"/></fig></p>
      <sec id="Sec9">
        <title>Safety</title>
        <p>Fasting glucose and glycosylated haemoglobin levels increased after introduction of LAN (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In patient 1, additional diabetic medication was necessary. Glargine up to 48&#xA0;IE was added on top of glibenclamide (5&#xA0;mg b.i.d). Patient 2 had to start diabetic medication (metformin 850&#xA0;mg t.i.d.; Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In these patients no transient elevated liver enzyme tests or tumor size increase was observed.</p>
      </sec>
    </sec>
    <sec id="Sec10">
      <title>Discussion</title>
      <p>We report two adequate controlled acromegaly patients during PEG-V monotherapy. Both could also be controlled after the conversion to combined treatment of PEG-V with long-acting SRIF analogs. During combined treatment, a dose reduction of PEG-V could be obtained between 80 and 150&#xA0;mg weekly to keep IGF-I levels within the age-adjusted reference range.</p>
      <p>During long-term combined therapy the weekly mean dose of PEG-V was 77&#xA0;mg [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>] while with PEG-V monotherapy a weekly mean dose of 130&#xA0;mg was necessary to reach an equal efficacy rate of more than 90% [<xref ref-type="bibr" rid="CR4">4</xref>]. Data from the long-term surveillance AcroStudy<sup>tm</sup> indicate that the mean patient on PEG-V therapy (of which around 1 out of 4 also use SRIF analogs) needs more than 21&#xA0;mg of PEG-V daily with an efficacy rate of around 60% [<xref ref-type="bibr" rid="CR10">10</xref>]. In our 2 patients that needed high-dose PEG-V during monotherapy, we observed dose reductions of 80 and 150&#xA0;mg per week, which reflect reductions in annual costs of around 35,000&#x2013;65,000 &#x20AC; respectively. When we take into consideration that high-dose SRIF analogs treatment costs between 19,000 and 25,000 &#x20AC;, depending on the country, our data indicate that in patients who need high-dose PEG-V during monotherapy, a significant reduction in costs can be achieved without loosing efficacy in normalizing IGF-I levels. The ratio behind the dose reduction in PEG-V during combined therapy of LAN and PEG-V is an increase of about 20% in PEG-V serum levels [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and the decrease in GH serum levels due to SRIF analog treatment. Also, a direct and indirect inhibition of IGF-I generation of the liver by SRIF analogs [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR11">11</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>] has been reported. Thus, during combined treatment PEG-V, which is a competitive antagonist of the GH receptor (GHR), has less GH to compete with, which reduces the necessary dose of PEG-V. Moreover, experiments in rodents, observed a decrease in the number of GHR on the liver due to a decrease of portal insulin concentration, which is a direct effect of SRIF analogs [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Therefore a further reduction in PEG-V dose can be possible.</p>
      <p>The difference in dose reduction we observed between both patients might be explained by the expression level of subtype of the somatostatin receptor (SSTR) on the pituitary adenoma. Patient 1 might have a lower expression of sst2 than patient B, as the efficacy of SRIF analogs in suppressing pathological GH secretion depends on the expression level of the sst subtypes on the pituitary adenoma [<xref ref-type="bibr" rid="CR17">17</xref>]. The expression level of sst2 on human pancreatic beta cells is high, but there remains controversy on the expression of sst3 and sst5 [<xref ref-type="bibr" rid="CR18">18</xref>]. In vivo, octreotide, mainly an sst2 agonist, decreases insulin concentration in contrast to Pasireotide (SOM 230) [<xref ref-type="bibr" rid="CR17">17</xref>]. Pasireotide, with high affinity to the sst1 and sst5 as well, has as Octreotide hyperglycemic effect. There for it unclear what the effect of SOM 230 is on the GHR expression on the liver. The alternative treatment with SOM 230 in patient 1 might lead to a dose reduction since GH levels will be lower but because of the possible higher expression of GHR a higher dose of PEG-V could be needed. Thus it is unclear what the net effect will be beneficial for the PEG-V dose reduction. Finally most studies which have been conducted with SOM 230 where with diabetic patient that had an optimal control. Therefore it is questionable if this patient would really benefit from SOM 230.</p>
      <p>SRIF analogs inhibits both exocrine and endocrine hormone secretion and to a lesser extent neuroendocrine tumor cell proliferation [<xref ref-type="bibr" rid="CR19">19</xref>]. Activation of sst receptors decreases intra-cellular c-AMP generation through the inhibition of adenylyl cyclase. There seems to be a role of the GHRH &#x2013;cAMP signaling pathway in somatotroph tumorgenesis. Ectopic GHRH production leads to somatotroph hyperplasia, however rarely to adenoma formation [<xref ref-type="bibr" rid="CR20">20</xref>]. GHRH induces c-AMP via a G-protein coupled receptor, the GHRH receptor, which induces GH production. Guanine nucleotide-binding protein (GNAS) mutation can lead to constitutively elevated c-AMP, protein kinase A activity, GH synthesis and secretion [<xref ref-type="bibr" rid="CR21">21</xref>]. About 40% of sporadic somatotroph adenomas harbor this mutation. Although the percentage of patients using PEG-V that develop a clinical significant increase in tumor size is reassuring low [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], the inhibitory effects of SRIF analogs on these mechanisms that are related to tumor growth also would suggest a more prominent role for the combination of both SRIF analogs and PEG-V, especially in patients with aggressive tumors and active disease that need high dose PEG-V during PEG-V monotherapy.</p>
      <p>The disadvantage of SRIF analogs treatment compared to PEG-V treatment with respect to carbohydrate metabolism is clearly demonstrated here. In healthy volunteers, administration of PEG-V did not influence the fasting insulin and glucose or response to oral glucose loading, in contrast with octreotide [<xref ref-type="bibr" rid="CR24">24</xref>]. Short term combined treatment resulted in a lower fasting glucose than with SRIF analogs alone, without a change in insulin levels [<xref ref-type="bibr" rid="CR11">11</xref>]. During long-term studies a decrease in glycosylated haemoglobin could be observed despite the reduction of insulin or oral diabetic medication [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. It seems that in the hierarchy of the beneficial effects on carbohydrate metabolism, PEG-V as monotherapy is superior to combined treatment. However, the combination is better than SRIF analogs monotherapy.</p>
      <p>In the past, both patients were treated with conventional radiotherapy. This was the pre-PEG-V era. To date, radiotherapy has become redundant from efficacy point of view. After a mean duration of 10&#xA0;years remission rates of 50&#x2013;60% are reported, but also 50&#x2013;80% of subjects develop hypopituitarism as well [<xref ref-type="bibr" rid="CR25">25</xref>]. Radiotherapy has some more disadvantages. A decreased quality of life has been reported which seems to be progressive over time [<xref ref-type="bibr" rid="CR26">26</xref>] and radiotherapy might also increase mortality (SMR 2.68) mainly due to cerebrovascular mortality [<xref ref-type="bibr" rid="CR27">27</xref>]. Our patients already showed some long-term side effects of radiotherapy as both have hypopituitarism. Cerebrovascular accidents have not occurred to date.</p>
      <p>These two cases are different from our previous reports, because these two patients were previously treated controlled with PEG-V daily monotherapy. Our previous studies included patients on SRIF analogs that still had an elevated IGF-I and therefore we did not have a direct comparison for dose reduction of PEG-V.</p>
      <p>In this case-study we start immediately with high-dose SRIF analogs treatment and we reduce weekly dose of pegvisomant by 50%. After 3 and 6 months, the PEG-V can be adjusted according to the serum IGF-I levels, If elevated, a higher weekly dose is necessary, while in case of normal IGF-I levels, one could further reduce the PEG-V dosages to find the lowest effective dose.</p>
      <p>In conclusion, these two case-reports show that a dose reduction in PEG-V is possible after the addition of a monthly high dose SRIF analogs. This might significantly reduce the annual costs. However, deterioration in the carbohydrate metabolism should be taken into account.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Conflict of interest</title>
      <p>W. W. de Herder and A. J. van der Lely are consultants for Novartis Pharma and Ipsen Pharma International. A. J. van der Lely is also a consultant for Pfizer International. R. A. Feelders is consultants for Novartis Pharma. The other author has nothing to disclose.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feenstra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>ten Have</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Beld</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>365</volume>
          <issue>9471</issue>
          <fpage>1644</fpage>
          <lpage>1646</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(05)63011-5</pub-id>
          <pub-id pub-id-type="pmid">15885297</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5&#xA0;years (median 2.2&#xA0;years) of follow-up in 86 patients</article-title>
          <source>Eur J Endocrinol</source>
          <year>2009</year>
          <volume>160</volume>
          <issue>4</issue>
          <fpage>529</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-08-0843</pub-id>
          <pub-id pub-id-type="pmid">19141604</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Aken</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2007</year>
          <volume>92</volume>
          <issue>12</issue>
          <fpage>4598</fpage>
          <lpage>4601</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-1234</pub-id>
          <pub-id pub-id-type="pmid">17895318</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Hutson</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Trainer</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Besser</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Barkan</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Katznelson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Klibanski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Herman-Bonert</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Freda</surname>
              <given-names>PU</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Friend</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Clemmons</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Johannsson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stavrou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Strasburger</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Hackett</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zib</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Scarlett</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Thorner</surname>
              <given-names>MO</given-names>
            </name>
          </person-group>
          <article-title>Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist</article-title>
          <source>Lancet</source>
          <year>2001</year>
          <volume>358</volume>
          <issue>9295</issue>
          <fpage>1754</fpage>
          <lpage>1759</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(01)06844-1</pub-id>
          <pub-id pub-id-type="pmid">11734231</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hodish</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Barkan</surname>
              <given-names>A</given-names>
            </name>
            <collab>Medscape</collab>
          </person-group>
          <article-title>Long-term effects of pegvisomant in patients with acromegaly</article-title>
          <source>Nat clin pract</source>
          <year>2008</year>
          <volume>4</volume>
          <issue>6</issue>
          <fpage>324</fpage>
          <lpage>332</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dekkers</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Biermasz</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Romijn</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Vandenbroucke</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Mortality in acromegaly: a metaanalysis</article-title>
          <source>J clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>1</issue>
          <fpage>61</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2007-1191</pub-id>
          <pub-id pub-id-type="pmid">17971431</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holdaway</surname>
              <given-names>IM</given-names>
            </name>
            <name>
              <surname>Bolland</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Gamble</surname>
              <given-names>GD</given-names>
            </name>
          </person-group>
          <article-title>A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly</article-title>
          <source>Eur J Endocrinol</source>
          <year>2008</year>
          <volume>159</volume>
          <issue>2</issue>
          <fpage>89</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-08-0267</pub-id>
          <pub-id pub-id-type="pmid">18524797</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elmlinger</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Kuhnel</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ranke</surname>
              <given-names>MB</given-names>
            </name>
          </person-group>
          <article-title>Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3)</article-title>
          <source>Clin Chem Lab Med</source>
          <year>2004</year>
          <volume>42</volume>
          <issue>6</issue>
          <fpage>654</fpage>
          <lpage>664</lpage>
          <pub-id pub-id-type="doi">10.1515/CCLM.2004.112</pub-id>
          <pub-id pub-id-type="pmid">15259383</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Somatostatin analog and pegvisomant combination therapy for acromegaly</article-title>
          <source>Nat Rev Endocrinol</source>
          <year>2009</year>
          <volume>5</volume>
          <issue>10</issue>
          <fpage>546</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="doi">10.1038/nrendo.2009.175</pub-id>
          <pub-id pub-id-type="pmid">19763127</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trainer</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Ezzat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>D&#x2019;Souza</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Layton</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Strasburger</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <article-title>A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly</article-title>
          <source>Clin Endocrinol</source>
          <year>2009</year>
          <volume>71</volume>
          <issue>4</issue>
          <fpage>549</fpage>
          <lpage>557</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2009.03620.x</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jorgensen</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Feldt-Rasmussen</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Frystyk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Kristensen</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Hagen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Orskov</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <issue>10</issue>
          <fpage>5627</fpage>
          <lpage>5631</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-0531</pub-id>
          <pub-id pub-id-type="pmid">16046586</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leung</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ballesteros</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Waters</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
          <article-title>Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <issue>12</issue>
          <fpage>4712</fpage>
          <lpage>4720</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.85.12.4712</pub-id>
          <pub-id pub-id-type="pmid">11134133</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Aken</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Badia</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>10</issue>
          <fpage>3853</fpage>
          <lpage>3859</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-0669</pub-id>
          <pub-id pub-id-type="pmid">18647806</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murray</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Chelly</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Umehara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis</article-title>
          <source>J Clin Investig</source>
          <year>2004</year>
          <volume>114</volume>
          <issue>3</issue>
          <fpage>349</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="pmid">15286801</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shishko</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Dreval</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Abugova</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Zajarny</surname>
              <given-names>IU</given-names>
            </name>
            <name>
              <surname>Goncharov</surname>
              <given-names>VC</given-names>
            </name>
          </person-group>
          <article-title>Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion</article-title>
          <source>Diabetes Res Clin Pract</source>
          <year>1994</year>
          <volume>25</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1016/0168-8227(94)90155-4</pub-id>
          <pub-id pub-id-type="pmid">7530621</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wurzburger</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Prelevic</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Sonksen</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Balint-Peric</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Wheeler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1993</year>
          <volume>77</volume>
          <issue>1</issue>
          <fpage>267</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.77.1.267</pub-id>
          <pub-id pub-id-type="pmid">8325951</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Lely</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Uitterlinden</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Boerlin</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bruns</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Poon</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Weckbecker</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Krahnke</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hofland</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Lamberts</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2004</year>
          <volume>89</volume>
          <issue>2</issue>
          <fpage>638</fpage>
          <lpage>645</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2003-031052</pub-id>
          <pub-id pub-id-type="pmid">14764775</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strowski</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Blake</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Function and expression of somatostatin receptors of the endocrine pancreas</article-title>
          <source>Mol Cell Endocrinol</source>
          <year>2008</year>
          <volume>286</volume>
          <issue>1&#x2013;2</issue>
          <fpage>169</fpage>
          <lpage>179</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mce.2008.02.007</pub-id>
          <pub-id pub-id-type="pmid">18375050</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Acromegaly pathogenesis and treatment</article-title>
          <source>J Clin Investigation</source>
          <year>2009</year>
          <volume>119</volume>
          <issue>11</issue>
          <fpage>3189</fpage>
          <lpage>3202</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI39375</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thorner</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Perryman</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Cronin</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Rogol</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Draznin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johanson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vale</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Horvath</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor</article-title>
          <source>J Clin Investigation</source>
          <year>1982</year>
          <volume>70</volume>
          <issue>5</issue>
          <fpage>965</fpage>
          <lpage>977</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI110708</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vallar</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Spada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giannattasio</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas</article-title>
          <source>Nature</source>
          <year>1987</year>
          <volume>330</volume>
          <issue>6148</issue>
          <fpage>566</fpage>
          <lpage>568</lpage>
          <pub-id pub-id-type="doi">10.1038/330566a0</pub-id>
          <pub-id pub-id-type="pmid">2825031</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buhk</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Psychogios</surname>
              <given-names>MN</given-names>
            </name>
            <name>
              <surname>Goricke</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hartz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schulz-Heise</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Klingebiel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Forsting</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bruckmann</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dorfler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jordan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buchfelder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knauth</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2010</year>
          <volume>95</volume>
          <issue>2</issue>
          <fpage>552</fpage>
          <lpage>558</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2009-1239</pub-id>
          <pub-id pub-id-type="pmid">19965922</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="other">Trainer PJ (2009) ACROSTUDY: the first 5&#xA0;years. Eur J Endocrinol 161(Suppl 1):S19&#x2013;24. doi:10.1530/EJE-09-0322</mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Parkinson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Drake</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Meeran</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Besser</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Trainer</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2002</year>
          <volume>87</volume>
          <issue>4</issue>
          <fpage>1797</fpage>
          <lpage>1804</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.87.4.1797</pub-id>
          <pub-id pub-id-type="pmid">11932320</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castinetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Morange</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dufour</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Regis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brue</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Radiotherapy and radiosurgery in acromegaly</article-title>
          <source>Pituitary</source>
          <year>2009</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>3</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-007-0078-y</pub-id>
          <pub-id pub-id-type="pmid">18175223</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klaauw</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Biermasz</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Hoftijzer</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Romijn</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Previous radiotherapy negatively influences quality of life during 4&#xA0;years of follow-up in patients cured from acromegaly</article-title>
          <source>Clin Endocrinol</source>
          <year>2008</year>
          <volume>69</volume>
          <issue>1</issue>
          <fpage>123</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.03169.x</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ayuk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Clayton</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Holder</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Bates</surname>
              <given-names>AS</given-names>
            </name>
          </person-group>
          <article-title>Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2004</year>
          <volume>89</volume>
          <issue>4</issue>
          <fpage>1613</fpage>
          <lpage>1617</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2003-031584</pub-id>
          <pub-id pub-id-type="pmid">15070920</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
